Vivesto AB (LON:0N4A)
London · Delayed Price · Currency is GBP · Price in SEK 0.0912
+0.0041 (4.71%)
Feb 12, 2026, 10:29 AM GMT
Vivesto AB Company Description
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden.
Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma.
The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers.
In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer.
The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022.
Vivesto AB was founded in 1988 and is headquartered in Solna, Sweden.
Vivesto AB
| Country | Sweden |
| Founded | 1988 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Erik Kinnman |
Contact Details
Address: Gustav III:s Boulevard 46 Solna, 169 73 Sweden | |
| Phone | 46 18 50 54 40 |
| Website | vivesto.com |
Stock Details
| Ticker Symbol | 0N4A |
| Exchange | London Stock Exchange |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0000722365 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Francois R. Martelet M.D. | Chief Executive Officer |
| Robert Maiorana | Head of Accounting and Acting Chief Financial Officer |
| Kai Wilkinson | Chief Technical Officer |
| Dr. Reinhard Koenig | Chief Scientific Officer |
| Urban Ekelund | IR Manager |
| Och Annette Ljungmark | Head of Accounting and Human Resources |
| John T. Cosby | Head of Regulatory Affairs |
| Dzianis Babrou | Head of Product Development |
| Henrik Rönnberg | Chief Medical Officer of Animal Health |
| Maria Nilsson Hagberg | Head of Regulatory Affairs |